Abstract

Biologics are drugs that are derived or synthesized from biological sources. A particular class are recombinant monoclonal antibodies. Their targeted application against distinct molecules of intercellular communication is of significant relevance in the treatment of tumor, inflammatory, or allergic diseases. But also in the context of allergen immunotherapy (AIT) they can be of special value. This is exemplified by the anti-IgE antibody omalizumab, which allows to achieve allergen tolerance in patients suffering from severe allergic reactions and increased risk of AIT-induced anaphylaxis. Furthermore, omalizumab administration during AIT effectively lowers the rsik of allergic side effects. This is demonstrated by a variety of studies and case reports of patients suffering either form respiratory, food, or insect venom allergy. Besides a direct blocking of IgE-mediated effects, T-cellular immune mechanisms might also be involved. Another interesting option is the applcation of recombinant IgG antibodes directed against specific epitopes of an allergen. Similar to AIT-induced IgG antibodies they can prevent the binding of allergens to IgE-antibodes as well as the hereby elicited allergic reactions.

Author Details

Authors

• Wolfgang Pfützner
• Mathias Schuppe

Departments

• Department of Dermatology and Allergology, Clinical-Experimental Allergology, Allergy Center Hessen, University Hospital Marburg, Philipps-University Marburg

Address

Prof. Dr. med. Wolfgang Pfützner, Klinik für Dermatologie und Allergologie, Allergie-Zentrum Hessen, Universitätsklinikum Marburg, Baldingerstraße, 35043 Marburg, Germany
Email: [email protected]

Citation